The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature Reviews Gastroenterology &Hepatology

• Publication date

  2012-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrgastro.2011.215PMID 22183185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pancreatic cancer.

  2021cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• A Randomized Trial

  2012cited by this paper
• An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy

  2011cited by this paper
• Pancreatic Ductal Adenocarcinoma (PDA) mice lacking Mucin 1 have a profound defect in tumor growth and metastasis

  2011cited by this paper
• Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.

  2011cited by this paper
• Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin

  2011cited by this paper
• Abstract 4434: Thermally targeted delivery of a c-Myc inhibitory peptide to breast tumors in vivo using elastin-like polypeptide

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Pancreatic cancer: understanding and overcoming chemoresistance

  2011cited by this paper
• Somatic variation and cancer: therapies lost in the mix

  2011cited by this paper
• Exploring the Genomes of Cancer Cells: Progress and Promise

  2011cited by this paper
• Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma

  2011cited by this paper
• GATA6 Activates Wnt Signaling in Pancreatic Cancer by Negatively Regulating the Wnt Antagonist Dickkopf-1

  2011cited by this paper
• Molecular signatures of pancreatic cancer.

  2011cited by this paper
• Stromal biology and therapy in pancreatic cancer

  2010cited by this paper
• International network of cancer genome projects

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• The patterns and dynamics of genomic instability in metastatic pancreatic cancer

  2010cited by this paper
• Signatures of mutation and selection in the cancer genome

  2010cited by this paper
• Molecular predictors of response to trastuzumab and lapatinib in breast cancer

  2010cited by this paper
• Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

  2010cited by this paper
• KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma

  2010cited by this paper
• The molecular pathology of cancer

  2010cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

  2010cited by this paper
• CD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cells

  2009cited by this paper
• Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.

  2009cited by this paper
• Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

  2009cited by this paper
• DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

  2009cited by this paper
• Pancreatic cancer: molecular pathogenesis and new therapeutic targets

  2009cited by this paper
• Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis

  2009cited by this paper
• Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene

  2009cited by this paper
• Overexpression of HOXB7 homeobox gene in oral cancer induces cellular proliferation and is associated with poor prognosis.

  2009cited by this paper
• A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells

  2009cited by this paper
• Linking somatic genetic alterations in cancer to therapeutics.

  2009cited by this paper
• Proteomics of Pancreatic Cancer

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• A Review on

  2008cited by this paper
• Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

  2008cited by this paper
• MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival

  2008cited by this paper
• Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays

  2008cited by this paper
• Identification of SMURF1 as a possible target for 7q21.3‐22.1 amplification detected in a pancreatic cancer cell line by in‐house array‐based comparative genomic hybridization

  2008cited by this paper
• Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Genome-Wide Analysis of Pancreatic Cancer Using Microarray-Based Techniques

  2008cited by this paper
• Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.

  2008cited by this paper
• Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis.

  2008cited by this paper
• Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells

  2007cited by this paper
• Stromal biology of pancreatic cancer

  2007cited by this paper
• The Genomic Landscapes of Human Breast and Colorectal Cancers

  2007cited by this paper
• The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer

  2007cited by this paper
• Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma

  2007cited by this paper
• Genome‐wide array‐based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome

  2007cited by this paper
• Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets

  2007cited by this paper
• MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

  2007cited by this paper
• Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

  2006cited by this paper
• Genetics and biology of pancreatic ductal adenocarcinoma.

  2006cited by this paper
• Molecular pathogenesis of pancreatic cancer.

  2006cited by this paper
• HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition.

  2006cited by this paper
• Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.

  2006cited by this paper
• Expression profiling identifies microRNA signature in pancreatic cancer

  2006cited by this paper
• Genome-wide aberrations in pancreatic adenocarcinoma.

  2005cited by this paper
• Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions

  2005cited by this paper
• The Genetic Basis of Sporadic Pancreatic Cancer

  2005cited by this paper
• Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration

  2005cited by this paper
• Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

  2005cited by this paper
• Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines

  2005cited by this paper
• Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

  2004cited by this paper
• High-resolution characterization of the pancreatic adenocarcinoma genome

  2004cited by this paper
• High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer.

  2004cited by this paper
• Genomic DNA-Chip Hybridization Reveals a Higher Incidence of Genomic Amplifications in Pancreatic Cancer than Conventional Comparative Genomic Hybridization and Leads to the Identification of Novel Candidate Genes

  2004cited by this paper
• Pancreatic cancer

  2004cited by this paper
• Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Identification of chromosomal imbalances in pancreatic carcinoma using comparative genomic hybridization.

  2003cited by this paper
• BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.

  2003cited by this paper
• Frequent amplification of 8q24, 11q, 17q, and 20q‐specific genes in pancreatic cancer

  2002cited by this paper
• Molecular pathogenesis of pancreatic cancer.

  2002cited by this paper
• Detection of Genetic Alterations in Pancreatic Cancers by Comparative Genomic Hybridization Coupled with Tissue Microdissection and Degenerate Oligonucleotide Primed Polymerase Chain Reaction

  2002cited by this paper
• Pancreatic cancer.

  2002cited by this paper
• Pancreatic cancer biology and genetics

  2002cited by this paper
• Epidemiology and risk factors

  2002cited by this paper
• Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas.

  2002cited by this paper
• Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases.

  2001cited by this paper
• A Comparison of DNA Copy Number Changes Detected by Comparative Genomic Hybridization in Malignancies of the Liver, Biliary Tract and Pancreas

  2001cited by this paper
• Progression model for pancreatic cancer.

  2000cited by this paper
• Genetic progression in the pancreatic ducts.

  2000cited by this paper
• Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH)

  2000cited by this paper
• Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.

  1999cited by this paper
• Differential MUC 1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples.

  1999cited by this paper
• Mucin gene and antigen expression in biliopancreatic carcinogenesis.

  1999cited by this paper
• The K‐ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium

  1999cited by this paper
• Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

  1998cited by this paper
• Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases.

  1998cited by this paper
• Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines.

  1998cited by this paper

• Iron oxide/lipid nanoparticles loaded with traditional Chinese medicine CGXJF constituents inhibit pancreatic cancer progression

  2025cites this paper
• The Construction of ceRNA Regulatory Network Unraveled Prognostic Biomarkers and Repositioned Drug Candidates for the Management of Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models

  2025cites this paper
• Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development.

  2025cites this paper
• Revolutionizing pancreatic cancer treatment with CAR-T therapy.

  2025cites this paper
• mRNA vaccine development and applications: A special focus on tumors (Review)

  2024cites this paper
• SAMD1 suppresses epithelial–mesenchymal transition pathways in pancreatic ductal adenocarcinoma

  2024cites this paper
• Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction

  2024cites this paper
• From Histopathology Images to Cell Clouds: Learning Slide Representations with Hierarchical Cell Transformer

  2024cites this paper
• An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum

  2024cites this paper
• An insight to PDAC tumor heterogeneity across pancreatic subregions using computed tomography images

  2024cites this paper
• Differential expression and bioinformatics analysis of exosome circRNAs in pancreatic ductal adenocarcinoma

  2023cites this paper
• Integrated Bioinformatics Analysis Identifies Crucial Biochemical Processes Shared between Pancreatitis and Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells.

  2023cites this paper
• Targeting mitochondrial transcription factor A sensitizes pancreatic cancer cell to gemcitabine.

  2023cites this paper
• pCCI: A machine learning patient-centric cell-cell interactions framework for cancer subtype classification

  2023cites this paper
• Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity.

  2023cites this paper
• Albumin conjugation promotes arsenic trioxide transport through alkaline phosphatase-associated transcytosis in MUC4 wildtype pancreatic cancer cells.

  2023cites this paper
• DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer

  2023cites this paper
• SAMD1 suppresses epithelial-mesenchymal transition (EMT) pathways in pancreatic ductal adenocarcinoma

  2023cites this paper
• Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma.

  2023cites this paper
• In vivo models of pancreatic ductal adenocarcinoma.

  2023cites this paper
• Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions.

  2023cites this paper
• Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing

  2022cites this paper
• Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

  2022cites this paper
• Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers

  2022cites this paper
• A comprehensive review of pancreatic cancer and its therapeutic challenges

  2022cites this paper
• Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy

  2022cites this paper
• Metabolomic analyses redefine the biological classification of pancreatic cancer and correlate with clinical outcomes

  2022cites this paper
• Multi‐omics analysis of intra‐tumoural and inter‐tumoural heterogeneity in pancreatic ductal adenocarcinoma

  2022cites this paper
• A Glycolysis-Related Gene Signature Predicting Survival in Pancreatic Ductal Adenocarcinoma.

  2021cites this paper
• Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma

  2021cites this paper
• An Emerging Role for the Unfolded Protein Response in Pancreatic Cancer

  2021cites this paper
• Molecular-targeted therapy of pancreatic carcinoma and its progress

  2021cites this paper
• Integrated Bioinformatics Analysis of Gene Expression Pro�les for Potential Biomarker Identi�cation Towards Early Therapeutic Intervention in Pancreatitis and Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight

  2021cites this paper
• Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer

  2021cites this paper
• GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses

  2021cites this paper
• Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact

  2021influential citation
• Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

  2021cites this paper
• Comprehensive Analysis of Expression, Prognosis and Immune In�ltrates for Kinesin Superfamily Members in Human Pancreatic Adenocarcinoma

  2021cites this paper
• Identi cation of Robust Immune‐Associated lncRNAs Signature for Immune Checkpoint Blockade and Prognosis in Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• An Immune-related lncRNAs Model for Prognostic of SKCM Patients Base on Cox Regression and Coexpression Analysis

  2020cites this paper
• Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy

  2020cites this paper
• High TXLNA Expression Predicts Favourable Outcome for Pancreatic Adenocarcinoma Patients

  2020cites this paper
• Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer

  2020cites this paper
• An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations.

  2020cites this paper
• Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression

  2020cites this paper
• Molecular radionuclide imaging of pancreatic neoplasms.

  2019cites this paper
• Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis.

  2019cites this paper
• β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer

  2019cites this paper
• SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.

  2019cites this paper
• The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA

  2019cites this paper
• Long-term Risk of Malignancy in Branch Duct Intraductal Papillary Mucinous Neoplasms.

  2019cites this paper
• Validation Strategy for Ultrasensitive Mutation Detection

  2018cites this paper
• Pancreatic cancer subtypes: a roadmap for precision medicine

  2018cites this paper
• Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis.

  2018cites this paper
• Novel three-lncRNA signature predicts survival in patients with pancreatic cancer

  2018cites this paper
• Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer

  2018cites this paper
• The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective

  2017cites this paper
• Bioengineering and biomechanical approaches for pancreatic cancer

  2017cites this paper
• Developing a genetic signature to predict drug response in ovarian cancer

  2017cites this paper
• Integrative Analysis of Transcriptome and MicroRNome Profiles inCholangiocarcinoma

  2017cites this paper
• PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors.

  2017cites this paper
• Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.

  2017cites this paper
• Pancreas specific expression of oncogenes in a porcine model

  2017cites this paper
• Morphological heterogeneity in ductal adenocarcinoma of the pancreas - Does it matter?

  2016cites this paper
• Assessing Drug Efficacy in a Miniaturized Pancreatic Cancer In Vitro 3D Cell Culture Model

  2016cites this paper
• miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma

  2016cites this paper
• MEK inhibition in pancreas cancer

  2016cites this paper
• Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells

  2016cites this paper
• Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.

  2016cites this paper
• Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?

  2016cites this paper
• A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT

  2016cites this paper
• KLF5, a new player and new target in the permanently changing set of pancreatic cancer molecular drivers

  2016cites this paper
• Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer

  2016cites this paper
• Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip.

  2016cites this paper
• HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer

  2016cites this paper
• Quantitative assessment of pancreatic cancer precursor lesions in IHC-stained tissue with a tissue image analysis platform

  2016cites this paper
• Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines

  2016cites this paper
• The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas

  2015cites this paper
• Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.

  2015cites this paper
• Pancreatic cancer genomics: where can the science take us?

  2015cites this paper
• Pancreatic cancer and FOLFIRINOX: a new era and new questions

  2015cites this paper
• Análisis de la heterogeneidad genética del adenocarcinoma ductal de páncreas y su relación con las características de la enfermedad

  2015cites this paper
• The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines

  2015cites this paper
• Prognosis Relevance of Serum Cytokines in Pancreatic Cancer

  2015cites this paper
• Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors

  2015cites this paper
• The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal

  2015cites this paper
• The genomic and metabolomic profiling of pancreas cancer

  2015influential citation
• Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma

  2015cites this paper
• CD109 Overexpression in Pancreatic Cancer Identified by Cell-Surface Glycoprotein Capture

  2014cites this paper
• Phase II , randomized , biomarker identi fi cation trial ( MARK ) for erlotinib in patients with advanced pancreatic carcinoma

  2014cites this paper
• Comparative Proteomic Profiling of Pancreatic Ductal Adenocarcinoma Cell Lines

  2014influential citation
• Measurement of Protein Kinase B Activity in Single Primary Human Pancreatic Cancer Cells

  2014cites this paper
• Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.

  2014cites this paper
• Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.

  2014cites this paper
• Pancreatic cancer genomics.

  2014cites this paper
• SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling

  2014cites this paper